Webcast / Audiocast

0 Comments

31 March 2017

Absorb II

Dr Paul Das

Comparison of everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3-year randomised, controlled, single-blind multicentre clinical trial.

Previous | Next

Summary

Dr Das presents the ABSORB II trial, the first-in-man study comparing BRS to Xience stents. Powered for two primary endpoints:

  • Superiority of Absorb over Xience in coronary vasomotion
  • Non-inferiority against Xience in late loss

Whilst some data remains encouraging, the trial has highlighted important areas of concern that require further thought, outlined in this excellent summary talk.

Summary

Dr Das presents the ABSORB II trial, the first-in-man study comparing BRS to Xience stents. Powered for two primary endpoints:

  • Superiority of Absorb over Xience in coronary vasomotion
  • Non-inferiority against Xience in late loss

Whilst some data remains encouraging, the trial has highlighted important areas of concern that require further thought, outlined in this excellent summary talk.

You have to be a BCIS member to access this content

Either Sign in or register to become a member, today! Join BCIS Sign In